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to adherence with ACE inhibitors, beta-blockers and ARBs. RESULTS: RAMQ data 
were obtained for a total of 82,018 patients with a diagnosis of CHF. Among these 
patients, 59.9% used an ACE inhibitor, 59.5% a beta-blocker, 28.4% an ARB. and 
12,344 (15.1%) had used spironolactone. Incidence of hyperkalemia (3.3% vs. 1.4%) 
and of gynecomastia (1.8% vs. 0.7%) was signiﬁcantly higher among spironolactone 
users compared to non users (p  0.001). Treatment compliance was signiﬁcantly 
lower with spironolactone compared to ACE inhibitors, beta-blockers and ARBs 
(45.6% vs. 56.1%, 59.7%, 57.0% respectively; p  0.001). Persistence to treatment 
over a one year period was also lower with spironolactone compared to ACE inhibi-
tors, beta-blockers and ARBs (50.7% vs. 64.5%, 70.4%, 66.3% respectively; 
p  0.001) CONCLUSIONS: Although the use of spironolactone may be beneﬁcial 
for patients with CHF, its usefulness is limited by the incidence of adverse events and 
its relatively poor treatment compliance.
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OBJECTIVES: To compute the frequency of the bradycardia associated with Atenolol 
Hydrochloride for possible toxic signal detection (SD) by extracting the data from the 
Canadian Adverse Drug Reaction Monitoring Program (CADRMP) ‘MedEffec’. 
METHODS: Appropriate statistical methods such as, Proportional Reporting Ratio 
(PRR); Reporting Odds Ratio (ROR); the Chi-Square (C2) statistic; Observed to 
Expected Ratio (O/E) and the Du Mouchel method were used for Adverse Drug Reac-
tion (ADR) signal detection. Signiﬁcance of C2 and other calculated statistics, e.g., PRR 
and ROR was based on a composite criterion of regulatory guidelines e.g. value q4.0 
for C2, and q3.0 for the rest to be considered as signal detection. RESULTS: The bra-
dycardia associated with Atenolol Hydrochloride was 8 (A) and bradycardia associ-
ated with all other antihypertensive medicines was 48 (C). All other adverse drug 
reactions (except bradycardia) caused by Atenolol Hydrochloride were 235 (B) and 
all other ADR (but not bradycardia) associated with all other antihypertensive medi-
cines (except Atenolol Hydrochloride) were 2593 (D). The value of PRR was 1.8134; 
Reporting Odds Ratio was 1.8390 and the C2 statistic value was 2.2915. The O/E 
ratio was 1.7047 and 1.6972 was the value of PRR calculated by the Du Mouchel 
method. CONCLUSIONS: Atenolol hydrochloride, a selective B1 receptor antagonist 
introduced in 1976 as a replacement for propranolol in the treatment of hypertension 
shows a number of serious and non-serious adverse drug reactions. Signal detection 
of bradycardia associated with Atenolol Hydrochloride was not found signiﬁcant by 
any of the statistical method. However, since the calculated statistics were consider-
able, albeit not signiﬁcant, the possibility of bradycardia-Atenolol Hydrochloride 
pairing should still be analyzed from larger databases.
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OBJECTIVES: To utilize an integrated medical-drug-dental claims database to under-
stand the relationship between periodontal disease, statin use, and cardiovascular 
disease (CAD) events. METHODS: Patients were selected from the 2005–2007 
MarketScan® Dental Database who had periodontal disease, based on diagnosis 
or dental procedure codes, and 12 months of continuous enrollment prior to the peri-
odontal disease diagnosis (index date). The Dental Database includes medical, phar-
macy, and dental records for 6.5 million patients. Patients were divided into two 
cohorts—treated and not treated with statins—and followed for 12 months for evi-
dence of CAD events. CAD patients were identiﬁed using ICD-9-CM diagnosis codes 
414.00–414.07 and 414.8–9. RESULTS: There were 157,915 patients identiﬁed having 
periodontal disease and meeting the enrollment criteria; 155,802 (98.7%) did not have 
a CAD event in the 12 months prior to the index date. Twenty-ﬁve percent (40,049) of 
patients with periodontal disease were on statins during this period. Post-periodontal 
diagnosis, the rate of CAD event was 0.42 percent (N  652) for statin-treated patients. 
The rate of CAD event post-periodontal diagnosis date was 1.16 percent (N  1808) 
for untreated patients. Controlling for differences in demographics and preexisting 
clinical conditions, patients not treated with statins prior to being diagnosed with peri-
odontal disease are 2.77 times more likely to have a CAD event in the following 12 
months than treated patients. CONCLUSIONS: Integrating dental claims with medical 
and drug claims provides an opportunity to follow a large cohort of patients and 
determine the relationships between oral and medical care and drug utilization. Statin 
treatment for an at-risk population with periodontal disease may mitigate the risk of 
a CAD event. A longer follow-up period will further elucidate this relationship.
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OBJECTIVES: Assess associations between the Deyo-Charlson comorbidity index 
(DCI) score and cardiovascular disease (CVD) event risk among primary (PR) and 
secondary risk (SR) dyslipidemia patients in a managed care setting. METHODS: A 
retrospective analysis of patients aged q18 years with laboratory results from a com-
plete ﬁrst lipid panel (index date) between January 1, 2002-February 28, 2005 was 
performed using an integrated managed care research database. Inclusion criteria were 
patients with minimum of 12 months pre- and post-index date follow-up, without 
lipid-modifying medication use at least 6 months prior to index date, and at least one 
of LDL-C, HDL-C, or TG at sub-optimal level per multiple national treatment 
guidelines. Associations between pre-index DCI score and 3-year CVD event risk was 
estimated between PR and SR patients using a multivariate logistic regression model 
after controlling for demographic and clinical variables. RESULTS: A total of 45,716 
patients were identiﬁed, 57.8% (n  26,407) were PR. Statistical signiﬁcance was 
observed between the 2 groups at baseline in terms of percent males (SR: 56.7% vs. 
48.3%: PR; p  0.0001), DCI score (SR: 0.16 o 0.43 vs. PR: 0.64 o 0.72; p  0.0001), 
LDL-C (SR: 129.4 o 35.1 vs. PR: 126.7 o 34.8 mg/dL; p  0.0001), HDL-C 
(SR: 42.0 o 11.2 vs. PR: 48.4 o 14.0 mg/dL; p  0.0001), and TG (SR: 179.1 o 79.3 
vs. PR: 161.1 o 79.1 mg/dL; p  0.0001). Regression analysis showed that every one 
unit increase in pre-index DCI score was associated with a 34% [Odds Ratio 
(OR): 1.34 (1.27–1.41); p  0.05] higher likelihood to experience a CVD event 
at 3 years among SR patients versus 32% [OR: 1.32 (1.20–1.46); p  0.05] for PR 
patients. CONCLUSIONS: SR dyslipidemia patients with a higher DCI score were 
associated with a higher CVD event risk versus PR patients. Further research on this 
association and subsequent impact on long-term clinical and economic outcomes is 
needed.
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OBJECTIVES: Assess associations between the Deyo-Charlson index (DCI) score and 
annual cardiovascular disease (CVD) event risk and attributable total health care costs 
(THC) between patients initiating niacin extended-release (NER) plus simvastatin 
(NER/S) and simvastatin plus ezetimibe (S/E) ﬁxed-dose therapy among patients with 
prior CVD. METHODS: A retrospective analysis of patients aged q18 years newly 
initiating S/E or NER/S therapy (initial therapy of NER added to existing simvastatin 
therapy) between January 1, 2001-June 30, 2006 (index date) was performed using a 
large integrated managed care research database. Patients with a minimum of 12 
months pre- and post-index date follow-up and a diagnosis of CVD at some time 
during 12 months prior to index date were included. Associations between pre-index 
date DCI score, CVD event risk, and THC [sum of inpatient, emergency room, and 
outpatient visit costs] were estimated using Cox proportional hazards regression 
model and multivariate generalized linear model, respectively. RESULTS: A total of 
7065 study patients were identiﬁed initiating S/E (n  6513) or NER/S (n  552). 
NER/S patients were signiﬁcantly younger (58.5 o 9.2 years vs. 61.3 o 10.2 years; p 
 0.0001) and more likely to be male (85.1% vs. 67.9%; p  0.0001). Pre-index date 
DCI score (1.3 o 1.3 vs. 1.4 o 1.6; p  0.1018) was comparable between the two 
groups. Cox regression showed that every one unit increase in pre-index date DCI 
score was associated with a 27% [Hazard Ratio (HR): 1.27 (1.22–1.32); p  0.05] 
higher likelihood to experience a post-index CVD event. Multivariate regression 
showed that every one unit increase in pre-index date DCI score was associated with 
a 38% (Coefﬁcient: 1.38, 95% CI: 1.30–1.47; p  0.0001) increase in mean annual 
CVD THC. CONCLUSIONS: High-risk patients with prior CVD and with an increas-
ing DCI score were associated with a higher CVD event risk and total annual CVD-
attributable THC. Further studies on dyslipidemia treatment strategies on higher risk 
patients are warranted.
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Despite substantial research showing that peripheral arterial disease (PAD) increases 
the risk for heart attack, stroke, amputation and other vascular-related conditions, 
PAD is potentially under-diagnosed and under-treated. Once diagnosed, research 
indicates that PAD merits aggressive management of all cardiovascular disease (CVD) 
risk factors. OBJECTIVES: The primary objective was to assess the prevalence of 
lower extremity PAD through Ankle-Brachial Index (ABI) measurement in patients at 
moderate CVD risk, with no overt vascular diseases nor diabetes mellitus. Secondary 
objectives included the prevalence and treatment of CVD risk factors and patient/phy-
sicians’ determinants for PAD under-diagnosis. METHODS: PANDORA Belgium was 
part of a non-interventional, cross-sectional, multi-centre study conducted in six 
European countries. Selection of general practitioners (GPs) was based on ABI mea-
surement training according ACC/AHA guidelines. RESULTS: A total of 119 GPs in 
Belgium recruited 1510 evaluable patients. The mean prevalence of asymptomatic 
PAD, deﬁned as ABI  0.90, was 7%, the lowest prevalence in the 6 countries (mean 
18%). Mean LDL-C for asymptomatic PAD patients was 125 mg/dl. Sixty-seven 
percent of untreated dyslipidemic subjects, diagnosed with asymptomatic PAD, had 
LDL-C  130 mg/dl. 32% of the Belgian patients were treated with statins. Patients 
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treated with statins tend to present less (44%) asymptomatic PAD than other patients 
(OR 0.56; 95%CI 0.30–1.05;p  0.07). Seventy-four percent of patients were 
aware of their CV risk, and smoking, high cholesterol, overweight and hypertension 
were identiﬁed by patients as the most important factors increasing the risk on 
CV disease. CONCLUSIONS: Asymptomatic PAD in subjects without CVD but 
at moderate risk was less prevalent in Belgium than in the other European countries, 
but was still signiﬁcantly correlated with classical CVD risk factors, especially 
smoking, hypertension, lipid proﬁle and age. It could be advisable to identify patients 
with such risk factors through ABI measurement and treat them accordingly as high 
risk individuals.
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CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH 
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UNITED STATES
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OBJECTIVES: To compare 5-year cardiovascular (CV) event reduction between 
patients treated with generic simvastatin therapy (ST) and niacin extended-release 
[NER]  simvastatin (NER/S) combination therapy among primary and secondary risk 
patients from a managed care organization’s perspective. METHODS: Two hypotheti-
cal managed care formularies, each consisting of 1,000,000 primary and secondary 
risk patients were modeled over a ﬁve year time horizon: a current formulary where 
all patients were treated with ST and a revised formulary where all the patients were 
treated with NER/S. Study patients with sub-optimal LDL-C, HDL-C, and/or TG at 
baseline were sampled from the HealthCore Integrated Research Database between 
January 1, 2000 and February 28, 2005. Package insert efﬁcacy of lipid medications 
in each formulary was applied to the study population. Post-treatment lipid values 
were evaluated according to U.S. lipid guidelines. Incremental reduction in CV events 
[myocardial infarction (MI), peripheral vascular disease (PVD), and stroke] among 
NER/S treated patients versus ST patients was estimated. Market share of NER/S over 
ﬁve years was assumed to be 1.5%. RESULTS: A total of 529,620 study patients were 
identiﬁed, having a mean age of 54 o 11 years, 45% female, and Deyo-Chrlson 
comorbidity score of 0.38 o 0.62. Patients treated with NER/S therapy demonstrated 
an incremental reduction of 1,515 CV events (27,218 vs. 28,733) over 5 years as 
compared to ST. Incremental reduction in stroke events in the same period were 
found to be 564 (10,144 vs. 10,708), MI events reduced by 631 (11,341 vs. 11,972), 
while PVD events reduced by 319 (5,733 vs. 6,052). CONCLUSIONS: Treatment 
with NER/S among primary and secondary risk dyslipidemia patients was associated 
with 5-year reductions in CV events compared to ST treated patients. Further studies 
assessing the addition of NER to ST or switching ST treated patients to NER/S therapy 
on clinical and economic outcomes are needed.
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OBJECTIVES: There is little evidence to compare effectiveness of individual 
Angiotensin Receptor Blockers (ARBs) in patients with chronic heart failure (CHF). 
This study compared four ARBs in reducing risk of mortality in everyday clinical 
practice. METHODS: A retrospective analysis was conducted on a national sample 
of patients diagnosed with CHF from October 1, 1996 to September 30, 2002 
identiﬁed from VA Electronic Medical Records, with supplemental clinical data 
obtained from chart review. After excluding patients with exposure to ARBs 
within the previous six months, four treatment groups were deﬁned based on 
initial use of candesartan, valsartan, losartan, and irbesartan between the index 
date (October 1, 2000) and the study end date (September 30, 2002). Time to death 
was measured concurrently during that period. A marginal structural model (MSM) 
controlled for sociodemographic factors, comorbidities, co medications, disease 
severity (left ventricular ejection fraction), and potential time-varying confounding 
affected by previous treatment (hospitalization). Propensity scores derived from a 
multinomial logistic regression were used as inverse probability of treatment weights 
(IPTW) in a generalized estimating equation to estimate causal effects. Results of MSM 
were compared to estimates obtained from traditional Cox regression models 
RESULTS: Among the 1,536 patients identiﬁed on ARB therapy, irbesartan was 
most frequently used (55.21%), followed by losartan (21.74%), candesartan(15.23%) 
and valsartan (7.81%). Adjusted hazard ratios from Cox regression found Candesar-
tan to reduce risk of mortality compared with Losartan (HR  0.60, 95% CI 0.37–
0.96). After adjusting for time-varying hospitalization in MSM utilizing IPTW, 
candesartan was found not signiﬁcant (OR  0.79, 95% CI  0.42–1.50). Irbesartan 
and valsartan were found to have similar effectiveness compared to losartan in both 
analyses. CONCLUSIONS: Effectiveness of ARBs in reducing mortality did not differ 
in patients with CHF in everyday clinical practice. Marginal structural models can be 
used to compare the effectiveness of multiple treatment groups and may improve 
risk-adjustment.
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OBJECTIVES: Statin therapy has established cardiovascular beneﬁts. Clinical guide-
lines set target cholesterol levels for populations at different risk levels. Treatment 
strategies include initial high-dose or conventional-dose statin followed by titration of 
patients failing to reach target. Empirical data on dose titration are scarce, but this 
model simulates potential cholesterol reductions for different populations, therapies 
and titration steps. METHODS: Patient-level cholesterol values before statin therapy, 
obtained from a large UK primary care database, were grouped into four patient 
groups in 0.5 mmol/L bands from  1–10: 1) no CVD or diabetes; 2) CVD, no dia-
betes; 3) diabetes, no CVD; 4) diabetes and CVD. Dose efﬁcacy studies enabled cal-
culation of percentage reductions in cholesterol from speciﬁed therapies in each band, 
variance, and the corresponding probability of reaching a speciﬁed target. For patients 
failing to reach target, the next higher statin dose was applied to the starting choles-
terol value. Mean cholesterol values of those above/below target were calculated and 
inserted into a lifetime, cardiovascular outcomes, Excel-based model using Framing-
ham risk equations and baseline parameters from statin clinical trials. RESULTS: For 
the 4 population groups, with a mean cholesterol reduction of 30% (SD 10%), propor-
tions reaching a 4 mmol/L target in one step were: 1) 24%; 2) 35%; 3) 40%; and 4) 
45%. Patients above target had two further titrations, each higher-dose therapy reduc-
ing cholesterol by a further 5%, with proportions increasing to 49%, 63%, 68% and 
71% respectively. Based on these proportions and using Framingham risk equations, 
corresponding 10-year CVD event rates were estimated as 27%, 42%, 29% and 55% 
for one-step therapy, and 23%, 39%, 26% and 52% following titration. CONCLU-
SIONS: Titration models provide insights about the impact of different therapy strate-
gies on cardiovascular outcomes for different population groups. The addition of cost 
data enables the cost-effectiveness of competing statin strategies to be estimated.
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OBJECTIVES: To analyze the percentage of patients treated with anti-hypertensive 
medication in mono or dual therapy that experienced a CV event. METHODS: A 
retrospective study of the Southwestern Ontario database which contains chart-
abstracted information from primary health care facilities in Ontario, Canada was 
performed. Patients with hypertension were identiﬁed as those with a recorded Blood 
Pressure (BP) exceeding 140/90 mmHg, chart entry of a diagnosis of hypertension, or 
use of anti-hypertensive medication. Patients treated either in mono or dual therapy 
with angiotensin II receptor blockers (ARBs), ACE Inhibitors (ACEIs) and Calcium 
Channel Blockers (CCBs) were included. The number of patients who experienced at 
least one CV event from 2003 to 2008 was recorded. CV events are stroke, myocardial 
infarction, congestive heart failure, peripheral vascular disease, coronary heart disease, 
atrial ﬁbrillation or transient cerebral ischemic attack. Due to the well known com-
parable safety proﬁle of the compounds, a safety analysis was not performed. 
RESULTS: A total of 53,064 patients treated with an ARB, ACEI or CCB in mono 
or dual therapy were identiﬁed. The proportions of treated patients who experienced 
a CV event were 4.3% on ARBs compared to 7.0% on ACEIs and 11.0% on CCBs. 
These differences were statistically signiﬁcant (p  0.001). Within the ARB class, the 
proportions of treated patients who experienced a CV event were 3.0% on irbesartan 
compared to 4.6% on losartan, 5.0% on valsartan and 5.0% on candesartan. These 
differences were statistically signiﬁcant (p  0.02). CONCLUSIONS: In patients 
treated in mono or dual therapy, those treated with an ARB experienced signiﬁcantly 
fewer CV events than those treated with an ACEI or a CCB. Amongst the ARB-treated 
patients, those treated with irbesartan as part of their therapy experienced signiﬁcantly 
less CV events than those treated with another ARB.
PCV13
EFFECTIVENESS OF ATORVASTATIN, PRAVASTATIN AND 
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OBJECTIVES: To compare the effectiveness of the most commonly prescribed statins 
in Brazil for the prevention of cardiovascular CV events, using indirect comparison 
meta-analysis. METHODS: A systematic review of the literature was conducted. 
Medline and the Cochrane Controlled Trials Register were searched for clinical 
trials that compared Pravastatin 40 mg, Simvastatin 40 mg or Atorvastatin 10 mg 
against control (placebo or usual care), for primary and secondary CV prevention. 
Full-texts of relevant abstracts were retrieved and evaluated in duplicate and indepen-
dently. Fixed-effect models were used for direct statin versus control comparisons, 
and the methodology described by Bucher et al. (1997) was used to derive indirect 
comparisons between statins. RESULTS: Eleven studies comparing Pravastatin 40 mg 
